Analysts at Cantor Fitzgerald Kept their Past ‘Buy’ rating on Shares Aldeyra Therapeutics (NASDAQ:ALDX), Set a $23.0000 Target Price per Share

May 17, 2018 - By Winifred Garcia

Investors sentiment decreased to 1.62 in 2017 Q4. Its down 1.51, from 3.13 in 2017Q3. It worsened, as 5 investors sold Aldeyra Therapeutics, Inc. shares while 8 reduced holdings. 9 funds opened positions while 12 raised stakes. 9.98 million shares or 45.35% less from 18.26 million shares in 2017Q3 were reported.

Perceptive Advsr Lc stated it has 0.7% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Deutsche State Bank Ag holds 1,700 shares. Royal Bank & Trust Of Canada stated it has 64 shares. 693,000 were accumulated by Adage Capital Partners Grp Ltd Company. Northern Tru Corporation reported 35,861 shares. Knoll L P stated it has 0.74% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). 62,100 were accumulated by Renaissance Technologies Ltd. Wells Fargo & Mn stated it has 13,540 shares. Tower Research Capital Ltd Liability Company (Trc) reported 24 shares or 0% of all its holdings. Dimensional Fund Advsr Lp, a Texas-based fund reported 50,923 shares. Ardsley Advisory reported 45,000 shares stake. Acadian Asset Mngmt Ltd Liability Co has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Prelude Lc owns 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 1,353 shares. Macquarie Group Limited has 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Peddock Capital Limited Company reported 752 shares or 0% of all its holdings.

Aldeyra Therapeutics (NASDAQ:ALDX) Rating Reaffirmed

They currently have a $23.0000 TP on Aldeyra Therapeutics (NASDAQ:ALDX). The target price by Cantor Fitzgerald would suggest a potential upside of 158.43 % from the company’s last stock close price. This has been revealed in a research report on Tuesday morning.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 2 analysts covering Aldeyra Therapeutics (NASDAQ:ALDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics has $2300 highest and $13 lowest target. $18’s average target is 102.25% above currents $8.9 stock price. Aldeyra Therapeutics had 2 analyst reports since January 26, 2018 according to SRatingsIntel. Cantor Fitzgerald maintained the stock with “Buy” rating in Thursday, March 29 report.

The stock increased 5.33% or $0.45 during the last trading session, reaching $8.9. About 117,719 shares traded or 25.81% up from the average. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has risen 55.45% since May 17, 2017 and is uptrending. It has outperformed by 43.90% the S&P500.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $175.02 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjgren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

More notable recent Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) news were published by: which released: “Earnings Scheduled For May 15, 2018” on May 15, 2018, also with their article: “Aldeyra Therapeutics (ALDX) Highlights Dry Eye Disease Phase 2a Clinical Trial Results” published on May 01, 2018, published: “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” on May 15, 2018. More interesting news about Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) were released by: and their article: “2 Small Biotechs To Consider” published on April 27, 2018 as well as‘s news article titled: “22 Stocks Moving In Friday’s Pre-Market Session” with publication date: May 11, 2018.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.